110 related articles for article (PubMed ID: 25183399)
21. Highly specific and quantitative activation of STATs in 3T3-L1 adipocytes.
Balhoff JP; Stephens JM
Biochem Biophys Res Commun; 1998 Jun; 247(3):894-900. PubMed ID: 9647789
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of STAT signaling in inflammation and tumorigenesis.
Adach A; Ellert-Miklaszewska A; Kaminska B
Methods Mol Biol; 2009; 512():265-78. PubMed ID: 19347282
[TBL] [Abstract][Full Text] [Related]
23. The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells.
Liby K; Voong N; Williams CR; Risingsong R; Royce DB; Honda T; Gribble GW; Sporn MB; Letterio JJ
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4288-93. PubMed ID: 16857804
[TBL] [Abstract][Full Text] [Related]
24. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus.
Heim MH
J Recept Signal Transduct Res; 1999; 19(1-4):75-120. PubMed ID: 10071751
[TBL] [Abstract][Full Text] [Related]
25. Acetylation modulates the STAT signaling code.
Wieczorek M; Ginter T; Brand P; Heinzel T; Krämer OH
Cytokine Growth Factor Rev; 2012 Dec; 23(6):293-305. PubMed ID: 22795479
[TBL] [Abstract][Full Text] [Related]
26. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening.
Hao W; Hu Y; Niu C; Huang X; Chang CP; Gibbons J; Xu J
Bioorg Med Chem Lett; 2008 Sep; 18(18):4988-92. PubMed ID: 18768317
[TBL] [Abstract][Full Text] [Related]
27. Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics.
Bowman T; Yu H; Sebti S; Dalton W; Jove R
Cancer Control; 1999 Oct; 6(5):427-435. PubMed ID: 10758575
[TBL] [Abstract][Full Text] [Related]
28. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
29. STAT activation and differential complex formation dictate selectivity of interferon responses.
Wesoly J; Szweykowska-Kulinska Z; Bluyssen HA
Acta Biochim Pol; 2007; 54(1):27-38. PubMed ID: 17351669
[TBL] [Abstract][Full Text] [Related]
30. Targeting STATs in neuroinflammation: The road less traveled!
Nabavi SM; Ahmed T; Nawaz M; Devi KP; Balan DJ; Pittalà V; Argüelles-Castilla S; Testai L; Khan H; Sureda A; de Oliveira MR; Vacca RA; Xu S; Yousefi B; Curti V; Daglia M; Sobarzo-Sánchez E; Filosa R; Nabavi SF; Majidinia M; Dehpour AR; Shirooie S
Pharmacol Res; 2019 Mar; 141():73-84. PubMed ID: 30550953
[TBL] [Abstract][Full Text] [Related]
31. Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4.
Wang J; Paradis P; Aries A; Komati H; Lefebvre C; Wang H; Nemer M
Mol Cell Biol; 2005 Nov; 25(22):9829-44. PubMed ID: 16260600
[TBL] [Abstract][Full Text] [Related]
32. Dynamics and non-canonical aspects of JAK/STAT signalling.
Mohr A; Chatain N; Domoszlai T; Rinis N; Sommerauer M; Vogt M; Müller-Newen G
Eur J Cell Biol; 2012; 91(6-7):524-32. PubMed ID: 22018664
[TBL] [Abstract][Full Text] [Related]
33. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.
Schust J; Sperl B; Hollis A; Mayer TU; Berg T
Chem Biol; 2006 Nov; 13(11):1235-42. PubMed ID: 17114005
[TBL] [Abstract][Full Text] [Related]
34. Activation of the signal transducers and activators of transcription signaling pathway by growth hormone (GH) in skin fibroblasts from normal and GH binding protein-positive Laron Syndrome children.
Freeth JS; Silva CM; Whatmore AJ; Clayton PE
Endocrinology; 1998 Jan; 139(1):20-8. PubMed ID: 9421393
[TBL] [Abstract][Full Text] [Related]
35. STAT proteins: novel molecular targets for cancer drug discovery.
Turkson J; Jove R
Oncogene; 2000 Dec; 19(56):6613-26. PubMed ID: 11426647
[TBL] [Abstract][Full Text] [Related]
36. Molecular Determinants for Unphosphorylated STAT3 Dimerization Determined by Integrative Modeling.
Sgrignani J; Olsson S; Ekonomiuk D; Genini D; Krause R; Catapano CV; Cavalli A
Biochemistry; 2015 Sep; 54(35):5489-501. PubMed ID: 26283080
[TBL] [Abstract][Full Text] [Related]
37. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity.
Page BD; Khoury H; Laister RC; Fletcher S; Vellozo M; Manzoli A; Yue P; Turkson J; Minden MD; Gunning PT
J Med Chem; 2012 Feb; 55(3):1047-55. PubMed ID: 22148584
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
39. Mutational analysis reveals separable DNA binding and trans-activation of Drosophila STAT92E.
Karsten P; Plischke I; Perrimon N; Zeidler MP
Cell Signal; 2006 Jun; 18(6):819-29. PubMed ID: 16129580
[TBL] [Abstract][Full Text] [Related]
40. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
